Papillary Renal Cell Carcinoma Clinical Trials

4 recruiting

Papillary Renal Cell Carcinoma Trials at a Glance

6 actively recruiting trials for papillary renal cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Bethesda, Dallas, and Atlanta. Lead sponsors running papillary renal cell carcinoma studies include National Cancer Institute (NCI), AstraZeneca, and Centre Leon Berard.

Browse papillary renal cell carcinoma trials by phase

Treatments under study

About Papillary Renal Cell Carcinoma Clinical Trials

Looking for clinical trials for Papillary Renal Cell Carcinoma? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Papillary Renal Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Papillary Renal Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Renal Cell Carcinoma+3 more
National Cancer Institute (NCI)65 enrolled13 locationsNCT04981509
Recruiting
Phase 1Phase 2

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI)100 enrolled1 locationNCT05665361
Recruiting
Not Applicable

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Urothelial CarcinomaMetastatic Urothelial CarcinomaRenal Cell Carcinoma+9 more
University of Texas Southwestern Medical Center600 enrolled1 locationNCT04623502
Recruiting

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

Papillary Renal Cell Carcinoma
AstraZeneca150 enrolled1 locationNCT07024680
Recruiting
Phase 2

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

Papillary Renal Cell Carcinoma Type 2
Centre Leon Berard72 enrolled12 locationsNCT05096390